Publications by authors named "Hualin Helen Li"
MK-1654 is a fully human monoclonal antibody with YTE mutations currently in phase III clinical trials for prophylactic use in protecting infants from human respiratory syncytial virus infection. We generated anti-idiotype (anti-ID) and anti-YTE antibodies against MK-1654 by panning with MorphoSys HuCal phage libraries, and used the antibodies in the development of MK-1654 pharmacokinetic (PK) and immune response (IR) assays. Detection of MK-1654 in nonhuman primate and human nasal wash samples showed combined use of anti-ID and anti-YTE antibodies can deliver desired sensitivity and accuracy in PK studies.
View Article and Find Full Text PDFArticle Synopsis
- Respiratory syncytial virus (RSV) is a major cause of severe lung infections globally, and developing an effective vaccine has been challenging, although recent advancements in vaccine technology bring hope for success.
- The new RSV vaccine V171 combines lipid nanoparticles and mRNA encoding an engineered version of the RSV F protein, which is designed to prompt robust immune responses within cells.
- Preclinical and Phase I trial results indicate that the mRNA vaccine is promising, and a new cell-based potency assay has been created to support its further clinical development by accurately measuring its effectiveness against a reference standard.